Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Olema Oncology clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, Australia, France, Spain, UK, Germany, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Canada, South Korea, Taiwan, Ireland, Israel, Brazil and Mexico registers with Olema Oncology as lead sponsor. Synced 17 Nov 2026
4Current trials
2Recruiting now
9Drugs in these trials
20Trial registers
At a glance

Olema Oncology is the lead sponsor of 4 current clinical trials in our USA, Australia, France, Spain, UK, Germany, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Canada, South Korea, Taiwan, Ireland, Israel, Brazil and Mexico registers. 2 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are Palazestrant, Fulvestrant and Letrozole. The most-studied condition is Metastatic Breast Cancer.

ClinicalTrials.gov trials by status

  • Recruiting250%
  • Active, closed250%

Trials by phase

  • Phase 1250%
  • Phase 3250%
01

Clinical trials sponsored by Olema Oncology

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767 · Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
Phase 3 Recruiting 2025-11 UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Canada, South Korea, Taiwan, Australia, Israel
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
NCT06784193 · Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC), Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase 1 Recruiting 2024-12 Ireland, USA, France, Spain, Australia
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
Phase 3 Active, closed 2023-11 UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, South Korea, Taiwan, Australia
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
NCT05508906 · Metastatic Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer
Phase 1 Active, closed 2022-08 USA, Australia

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Olema Oncology trials

9 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Olema Oncology trials

10 conditions
Metastatic Breast Cancer4Breast Cancer3ER Positive Breast Cancer2Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)1Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)1Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)1Locally Advanced Breast Cancer1Advanced Breast Cancer1ER-positive Breast Cancer1HER2-negative Breast Cancer1
06

Questions about Olema Oncology trials

How many clinical trials does Olema Oncology sponsor?

Olema Oncology is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA, Australia, France, Spain, UK, Germany, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Portugal, Canada, South Korea, Taiwan, Ireland, Israel, Brazil and Mexico registers, as of the registry sync on 17 November 2026. Completed and withdrawn studies are not counted.

Are Olema Oncology trials recruiting?

Yes. 2 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Olema Oncology testing?

Its current trials name 9 drugs and biologicals as interventions. The most frequent are Palazestrant (4), Fulvestrant (2), Letrozole (2), Ribociclib (2) and Alpelisib (1). The number in brackets is how many of its trials name each drug.

Does Olema Oncology have clinical trials in Ireland?

Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 17 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.